TOKYO--(BUSINESS WIRE)--PeptiGrowth Inc. (Headquarters: Chiyoda-ku, Tokyo, President: Jiro Sugimoto) has successfully developed a novel peptide called TGF?1 inhibitor (TGF?1 binding peptide) which binds to TGF?1 to inhibit its activity.

Development of Synthetic Peptide Growth Factors by PeptiGrowth

Conventional growth factors and cytokines used in the manufacturing of regenerative medicine and cell therapy products are facing various challenges such as lot-to-lot quality variation, potential contamination with biological impurities, low stability, and high cost. PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as conventional growth factors and cytokines, and that can address and solve all these challenges. Its peptides are completely chemically synthesized and animal component-free.

About TGF?1 inhibitor (TGF?1 binding peptide) (Product code: PG-002)

• Inhibitory activity against TGF?1 (ligand)

Existing small molecule inhibitors must enter the cell to inhibit TGF?1 activity. On the other hand, PG-002 is a peptide that binds to and exhibits inhibitory activity against TGF?1 (ligand), which acts outside cells. The inhibitory activity against TGF?1 was measured by SBE Reporter Assay, and PG-002 showed 100% inhibitory activity at 10nM against 0.13nM TGF?1 (Figure A). Using the panel assay, we also confirmed that it does not inhibit other signaling pathways. We recommend using PG-002 when the neutralization of TGF?1 is required in cell culture.

• Product Overview

About HGF Alternative Peptide (c-Met Agonist) (Product code: PG-001)

Prior to TGF?1 inhibitor, PeptiGrowth has launched a synthetic peptide growth factor, PG-001, which has the same functions as native Hepatocyte Growth Factor (HGF). PeptiGrowth demonstrated that PG-001 activates c-Met (HGF-target receptor) by phosphorylation and supports cell (HUVEC) proliferation as shown in Figure B and C above respectively.

To Purchase PeptiGrowth Products

To purchase PeptiGrowth products mentioned in this article, please contact the agent in North America, Mitsubishi International Food Ingredients, Inc.

About PeptiGrowth

PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. with the missions to address various challenges that regenerative medicine and cell therapy industry is facing and to contribute to its growth. Since its foundation, PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as the conventional growth factors and cytokines by joint development with PeptiDream.

Following HGF Alternative Peptide and TGF?1 inhibitor, PeptiGrowth is planning to launch the next product by the end of March, 2022. Details will be updated on its website upon release.

Contacts

Mitsubishi International Food Ingredients, Inc.

Jes Kuruvilla, PhD

Tel : + 1 (201) 681-1268

E-mail: [email protected]